What this means
Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- Mice with paediatric brain tumour cells, plus lab-grown cells
- Kind of research
- A study
The science
- Original title
- Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition.
- Authors
- Guiho R, Hamdi H, Cooksley G et al.
- Journal
- Neuro-oncology
- Published
- Oct 29, 2026
- Study type
- Study
- PMID
- 42954328 ↗
Abstract
Background
Chemo-, radio-, and targeted therapies can induce a stable growth arrest known as therapy-induced senescence (TIS), which may be therapeutically exploited using senolytic compounds that selectively eliminate senescent cells. Children with BRAF-V600E-driven brain tumours are commonly treated with low-dose chemotherapies and MAPK inhibitors, alone or in combination, often with good initial responses. However, a majority of patients experiences tumour regrowth following treatment withdrawal. Here, we investigate the contribution of TIS to treatment response and relapse, and assess the therapeutic potential of senolytics in preclinical models of paediatric BRAF-V600E glioma.
What they did
Preclinical models of paediatric low-grade glioma were analysed in vitro or following orthotopic transplantation into mice and treated with Dabrafenib, Trametinib, Tovorafenib or Vinblastine. Senescence was assessed using molecular and cytological markers. Sensitivity to senolytic compounds was evaluated using in vitro dose-response assays and in vivo treatment studies.
What they found
Trametinib induced a robust senescent phenotype in BT-40 tumours in vivo, characterised by activation of a senescence-associated secretory phenotype and expansion of IBA-1-positive myeloid cells. In vitro, senescence was induced in BT-40 cells following treatment with MAPK inhibitors and Vinblastine, and was similarly observed in H9-derived human neural stem cells expressing BRAF-V600E. Navitoclax was identified as a potent senolytic against senescent BT-40 cells, primarily through inhibition of the anti-apoptotic protein BCL-xL. In vivo, combined Trametinib and Navitoclax treatment ablated senescent tumour cells, significantly reduced tumour regrowth after treatment withdrawal, and improved survival. These findings demonstrate that Navitoclax enhances Trametinib's anti-tumour efficacy and limits tumour relapse following treatment cessation.
The authors' abstract, grouped under plain headings from its own section labels.
Guiho R, Hamdi H, Cooksley G et al. Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition. Neuro-oncology. 2026. doi:10.1093/neuonc/noag270. PMID: 42954328. https://pubmed.ncbi.nlm.nih.gov/42954328/
Related research
New fluorescent sensor detects cells aging from cancer and lung drugs
Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.
Neuronal receptor remodeling in the aging periosteum: From single-cell atlases to regenerative targets.
The periosteum is the most densely innervated compartment of the skeleton and harbors periosteal stem cells expressing a broad repertoire of neuronal receptors traditionally associated with the nervous system.
A vaccine-style treatment in mice eased diabetes signs and aged cell markers
Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.
Aging cells that support stem cells may disrupt them through chemical signals
This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.
Cx43 protein may boost breast cancer drug response in lab tests
Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.
A new vaccine clears aging cells in mice and may extend lifespan
Researchers made a vaccine aimed at old, worn-out cells called senescent cells. In mice, it cleared some of these cells and helped metabolism. This is early work, so it does not show the vaccine would help people.
See all research on Senolytics →